Premature Menopause (POI): Pregnancy Chances and Options

Sometimes, but rarely without help. Premature ovarian insufficiency (POI) means the ovaries have lost most of their activity before 40, yet unlike menopause at the usual age they can switch back on unpredictably, so a small minority of women conceive naturally after diagnosis. For most women who want a pregnancy, the route that reliably works is IVF with donor eggs.

The 2024 ESHRE guideline, written with the American Society for Reproductive Medicine, makes three points that frame every decision below: POI substantially reduces the chance of natural conception; ovarian activity can still occur in POI that was not caused by surgery; and oocyte donation is an established option. For what POI is and what causes it, see our overview of premature ovarian failure.

A diagnosis should rest on a pattern and a blood test, not on one missed period or one low AMH. ESHRE's 2024 criteria are:

• Absent or irregular periods for at least four months, and
• An FSH level above 25 IU/l. One result is enough when the picture is clear; the test is repeated after 4-6 weeks if it is not, and it does not need to be timed to a cycle day.

The same guideline says pregnancy must be excluded first, and that the pill and other hormonal contraception can hide or cause irregular periods and lower FSH, so they may need to be stopped before POI can be confirmed. AMH should not be the primary test, though it can help when FSH is inconclusive. Low estradiol supports the diagnosis but does not make it on its own.

ACOG lists what else can stop periods in a young woman: pregnancy, polycystic ovary syndrome, hypothalamic amenorrhoea, thyroid disease and raised prolactin. A low AMH with regular periods is a different situation, diminished ovarian reserve, and it is not the same as POI.

Low, and hard to predict for any one person. The best data come from long-running French hospital cohorts:

• Of 358 women with POI of unknown cause, 86 (24%) showed signs that ovarian function had resumed, most within a year of diagnosis, and 15 had a spontaneous pregnancy, about 4 in 100 (Bidet et al, 2011).
• Of 507 women followed for an average of about three and a half years, 23% had ovarian function resume. Cumulative pregnancy incidence was 3.5% across the whole cohort and 15.3% among the women whose function resumed; in nearly half of them the resumption later stopped (Bachelot et al, 2017).
• In a survey of 324 women diagnosed at the same Paris centre, the spontaneous pregnancy rate was 8.6%; only 324 of 985 women referred could be surveyed (Cambray et al, 2023).

In the 2011 cohort, resumption was more likely with a family history of POI, periods that had started and then stopped rather than never starting, follicles visible on ultrasound, and higher inhibin B and estradiol. Those are group-level signals; they do not tell any individual woman whether she will ovulate again.

Yes, if a pregnancy is not wanted. Because the ovaries can restart without warning, ESHRE 2024 advises women with POI not caused by surgery to use contraception if they wish to avoid pregnancy, and says clinicians should make clear that hormone replacement therapy (HRT) is not contraception. ACOG adds that a missed period in a woman with POI warrants a pregnancy test. Women whose POI followed removal of both ovaries cannot conceive with their own eggs.

Usually not, and a clinic should say so plainly. Fertility drugs stimulate follicles that exist; they cannot create them. ESHRE 2024 states, on moderate-quality evidence, that no intervention has been reliably shown to increase ovarian activity or natural conception rates in POI.

The Paris survey shows how families were actually built. In that cohort of 324, among the women who wanted children and had them after diagnosis, 53.9% did so through donor eggs, 25.8% through a spontaneous pregnancy, 13.5% through adoption and 5.6% after ovarian stimulation. Own-egg treatment is not impossible, but it is the least common route in that cohort.

Eggs from a donor are fertilised with a partner's or donor sperm and the embryo is transferred to the recipient's uterus. Because the eggs come from someone else, this route does not depend on the ovaries recovering. More on the decision itself is in when to consider donor sperm or eggs.

ESHRE 2024 treats these as high-risk pregnancies, to be managed in a suitable obstetric unit, and asks couples to tell their obstetric team the pregnancy came from donor eggs. Before treatment, the guideline recommends finding the cause of POI and checking heart, metabolic and thyroid health. Women with Turner syndrome need cardiology assessment before any pregnancy is planned. If a sister is the donor in POI with no known cause, ESHRE notes she may share the genetic risk and is more likely to have her stimulation cycle cancelled.

In India, the ART (Regulation) Act 2021 sets the rules. Donor eggs must be provided through an ART bank registered under the Act. Donors must be aged 23 to 35, may donate only once in their life, and no more than seven eggs may be retrieved. One donor's eggs may go to only one couple, and the couple or woman receiving them must buy 12 months of insurance cover for the donor.

Only where POI can be seen coming. ESHRE 2024 says fertility preservation can be considered before treatment that may cause POI, such as chemotherapy, pelvic radiotherapy or ovarian surgery (see fertility preservation for cancer patients), and should be discussed with any woman known to be at risk. Once POI is established, it states, in most women there is no opportunity for preservation, because the follicle pool is already depleted.

That is why freezing is a conversation for before, not after. What egg freezing involves, and what it costs, is covered in our egg freezing guide.

A POI diagnosis often lands years before anyone expected to think about menopause, and ESHRE asks clinicians to give it with time for questions and to offer psychological support. The practical work-up in the 2024 guideline includes:

• Chromosome analysis and FMR1 (fragile X) premutation testing for all women whose POI has no medical or surgical cause, after discussing what the results could mean
• 21-hydroxylase antibodies when the cause is unknown, since a positive result means adrenal testing
• A thyroid (TSH) test
• A bone density (DXA) scan at diagnosis where available, and blood pressure, lipid and diabetes checks
• Hormone therapy until the usual age of menopause, recommended for bone, heart and brain health whether or not there are symptoms; the regimen is set with the prescribing doctor

ACOG recommends referral to a reproductive endocrinology and infertility specialist when the woman wants to discuss pregnancy, and review at least yearly after diagnosis. A fertility consultation should confirm the diagnosis against the criteria above if that has not been done, and then set out the realistic routes: waiting for spontaneous ovarian activity, donor eggs, or adoption.

No treatment has been shown to reliably restore ovarian function in POI. ESHRE 2024 makes that a strong recommendation: women should be told no intervention has been reliably shown to increase ovarian activity or natural conception.

Not established:

• Platelet-rich plasma (PRP) injected into the ovary. The one randomised trial retrieved, PROVA (83 women under 38 with poor response to IVF, not POI), found no difference in mature eggs (2.8 with PRP vs 3.1 without) or implantation. Its authors say the result may not carry over to POI, but no randomised trial in POI itself was found. A 2026 umbrella review rated the certainty of PRP evidence very low to moderate, with variable effects on pregnancy and live birth.
• In vitro activation (IVA), where ovarian tissue is removed, treated and regrafted. A 2021 pooling of eight studies counted 177 treated women, 26 pregnancies and 18 live births, with no comparison group, so it cannot show IVA caused any of them.
• DHEA, herbal products and supplements. No trial retrieved for this article shows DHEA restores ovarian function in POI, and ESHRE finds insufficient evidence for other supplements and herbal medicines.
• Acupuncture. ESHRE finds limited evidence even for menopausal symptoms in POI, and no benefit from adding it to hormone therapy.
• Any individual prediction of natural conception. The cohort figures above come from single French referral centres and mostly women with POI of unknown cause; they may not describe women whose POI followed cancer treatment, or women in India.

A clinic offering an unproven procedure should be able to show the controlled trial behind it. If it cannot, the honest description is experimental, and it should not delay a decision about donor eggs when time matters.